The start-up claims in clinical trials over 90 % achieved type 2 diabetes reversal and 92 % eliminated all diabetes medication within 90 days of joining the twin service
The company has already received the emergency use authorization (EUA) from the Drug Controller General of India (DCGI) for ZyCoV-D to be administered in three doses on August 20
Bharat Biotech has been submitting data to the WHO on a rolling basis and submitted additional information at WHO’s request on September 27th 2021
_256_384.jpg)
In Q2FY22, growth from Covid-driven products in the domestic branded formulation sales should dissipate on a QoQ basis as new covid cases have declined sharply. Vishal Manchanda, research analyst Nirmal Bang gives a preview of pharma companies in this report
This product will be manufactured at Lupin’s Pithampur facility In India
A growing number of studies have shown the benefit of a third dose of Covid-19 vaccine in immunocompromised subjects
The rates for over 400 procedures were revised
The company will use the capital for building its team, product development, marketing, and setting up in-school clinics to deliver connected health to one million families
The transaction is anticipated to close in the first quarter of 2022
A total of 8308 stores are open across India and medicines are priced at affordable rates
Subscribe To Our Newsletter & Stay Updated
